Malignant peripheral nerve sheath tumors (MPNST) are aggressive spindle cell neoplasms that may occur sporadically, often in association with radiation exposure, or in the clinical context of Neurofibromatosis type 1. MPNST are known to harbor genetic alterations affecting the function of polycomb repressive complex 2 (PRC2), resulting in profound changes to global H3K27me3 levels. Recent evidence suggests a link between the polycomb complex and DNA methylation. Given the established epigenetic alterations found in MPNST, we aimed to further explore global methylation changes including 5-methylcystosine (5mC), 5-hydroxymethylcytosine (5hmC), and H3K27me3 levels using previously validated immunolabeling protocols in a representative cohort of 28 peripheral nerve sheath tumors (MPNST [n ¼ 8], localized cutaneous neurofibroma [n ¼ 10], and plexiform neurofibroma [n ¼ 10]). MPNST showed significantly decreased levels of H3K27me3 (p < 0.0002) and 5mC (p ¼ 0.0001) with levels of 5hmC showing borderline statistical significance (p ¼ 0.05) when compared to localized and plexiform neurofibromas. Immunohistochemical findings of decreased H3K27me3 and 5mC further our understanding of global epigenetic alterations observable in MPNST and may provide insight into the basis of tumor progression as well as prognostic and treatment implications in the future.
INTRODUCTION
Malignant peripheral nerve sheath tumors (MPNST) are malignant neoplasms of nerve sheath differentiation (1) that often recur, causing great patient morbidity and mortality (2, 3) . MPNST are frequently encountered in the setting of Neurofibromatosis type 1 (NF1) but may also occur sporadically or in patients with prior radiation treatment. MPNST are known to harbor genetic alterations affecting polycomb repressive complex 2 (PRC2) activity, resulting in global chromatin changes (4, 5) .
PRC2 belongs to the polycomb group proteins and is composed of 4 proteins: EED, RbAp46/48, SUZ12 and 1 of the 2 methyltransferases EZH1 or EZH2 (EZH1/2). PRC2 catalyzes the addition of 2 or 3 methyl groups to lysine 27 of the core histone H3 (H3K27), which results in increased chromatin compaction and transcriptional repression of PRC2 target genes (6) . PRC2 associated alterations have been seen in a variety of tumor types and contribute to tumorigenesis through dysregulation of the cell cycle and gene expression (7) . PRC2 alterations, particularly in the SUZ12 component, may potentiate RAS pathway activation through interactions with NF1 gene mutations common to NF1-associated malignancies, including MPNST (6) . Furthermore, recent findings demonstrate that loss of either EED or SUZ12 are observed in 80% of MPNST cases (4) .
A clinically pertinent downstream effect of PRC2 inactivation through gene mutation in PRC2 complex members is the global decrease of H3K27 trimethylation (H3K27me3) levels (2, 7-10), thereby linking genomic alterations with global epigenetic resculpting and ultimately resulting in profoundly changed gene expression (11) (12) (13) . As a clinical biomarker, H3K27me3 loss in neoplastic cells has shown utility for prognosis (9) , origin (14) , and diagnosis (2, 12, 15) of MPNST.
In addition to histone modifications, covalent modification of DNA represents another important mechanism for epigenetic regulation. In particular, methylation of the 5-position of cytosines in CpG dinucleotides (5mC) has been associated with gene silencing (16) . 5mC marks are established and maintained by DNA methyltransferases (DNMT). Whereas DNA methylation patterns are tightly controlled during normal development, cancers often show a gain of CpG methylation in promoters of putative tumor suppressor genes and in a background of a loss of global 5mC levels (17, 18) .
Importantly, the PRC2 group functions to repress genes by multiple mechanisms. Recent evidence suggests that EZH2 can direct DNMTs to target sites (10) . In addition, increased H3K27me3 levels, mediated by PRC2, allow recruitment of the PRC1 complex, which ubiquitinates histone H2A lysine 119. This leads to further recruitment of DNMTs to DNA (19) . PRC2 therefore holds a central role in controlling DNA methylation, and PRC2 inactivation represents 1 possible mechanism resulting in global DNA hypomethylation. Along these lines, we and others have previously identified a decrease in global 5mC in pediatric diffuse intrinsic pontine glioma (DIPG) (20) . In this cancer, a H3-K27M mutation in H3F3A or HIST1B leads to an inability of EZH2 and PRC2 to disengage from H3, causing global decreases in H3K27me3 and DNA methylation (21) . 5mC can be further oxidized to 5-hydroxymethylcytosine (5hmC) in an enzymatic process that involves members of the 10-11 translocated protein family (TET1, TET2, and TET3) (18, 20) . Although the role of 5hmC in transcriptional regulation is not very well understood, 5hmC can be found in promoters of both active and repressed genes and often shows an association with gene loci that show "bivalent" chromatin marks characterized by the presence of repressive (H3K27me3) and active (H3K4me3) marks. Furthermore, 5hmC is decreased in a large number of cancers (18, 22, 23) and may be an early event in carcinogenesis (22) .
Given the complex interactions between DNA methylation marks and histone modifications as well as the known loss of H3K27me3 in MPNST, we aimed to address the association between global levels of H3K27me3, 5mC and 5hmC in nerve sheath tumors.
MATERIALS AND METHODS

Patients and Tumor Samples
MPNST, neurofibroma, and plexiform neurofibroma cases from 2003 to 2014 were collected in accordance with institutional ethical research policies from cases at Johns Hopkins Hospital with sufficient tissue for serial sections. The diagnosis was confirmed by 1 of the authors (F.J.R.). A total of 28 cases were gathered from Johns Hopkins records, consisting of 9 MPNST (from 8 patients), 10 localized cutaneous neurofibromas, and 10 plexiform neurofibromas. Ages at diagnosis ranged from 14 to 64 years of age with median ages of diagnosis at 35 years for MPNST, 37.5 years for neurofibroma, and 23 years for plexiform neurofibroma (Table 1) . A total of 25 of 28 (89%) patients had a diagnosis of Neurofibromatosis 1.
Immunohistochemistry
Cases were stained and evaluated following a previously published protocol (20) that is summarized here briefly. Conditions have been extensively validated using positive and negative controls as outlined in our prior publications (20, 22, 34) . Tissues embedded in paraffin were cut at 5 lm, deparaffinized and rehydrated in standard protocol. Samples were treated with citrate buffer (pH 6.0) followed by 3.5 N HCl at room temperature and finally TBS-Tween buffer (Sigma, St. Louis, MO) equilibration. Immunohistochemical staining was performed with antibodies for mouse monoclonal 5-methylcytosine specific antibody (Calbiochem, EMD Chemicals Inc., San Diego, CA) at 1:2000 dilution, and rabbit polyclonal 5 hydroxymethylcytosine specific antibody (Active Motif, Cat # 39769, Carlsbad, CA) applied at 1:20,000 dilution. Antibodies for 5-methylcytosine and 5-hydroxymethylcytosine were incubated at room temperature for an hour as described previously (22) . The mouse monoclonal anti-H3K27me3 (ab6002, Abcam, Cambridge, MA) was applied overnight at 4 C at 1:200 dilution as described previously (17) . Slides were counterstained with hematoxylin for evaluation. H-scores were calculated by multiplying stain intensity (0: negative staining; 1: weak staining; 2: strong staining) by the percentage (0-100) of neoplastic cells exhibiting staining in accordance to protocol previously published (20) . Nonneoplastic cells in each case were used as an internal control.
Statistical Analysis
Statistical analysis using one-way analysis of variance (ANOVA) of H-scores was performed using Graph-Pad Prism 6 Software (Graph-Pad Software, La Jolla, CA).
RESULTS
MPNST Have Decreased H3K27-Trimethylation Compared With Localized Cutaneous and Plexiform Neurofibromas
H3K27me3 immunohistochemistry labeled nonneoplastic cell elements in all tumors studied, including endothelium, fibroblasts, and inflammatory cells. MPNST in particular demonstrated significantly decreased immunoreactivity in neoplastic cells with preserved immunoreactivity in nonneoplastic elements (Fig. 1) . Median H3K27me3 H-scores for MPNST were 30 (range 10-120) with 5 (of 8 cases tested) demonstrating H-scores of 30. Median H3K27me3 H-scores for localized and plexiform neurofibroma were similar, 140 (range 100-180) and 160 (range 120-180), respectively. The H-score differences were statistically significant (p ¼ 0.0002, one-way ANOVA) with the differences explained by the decrease in H3K27me3 in the MPNST group compared to localized and plexiform neurofibromas (Fig. 2) .
MPNST Have Decreased 5mC Compared with Localized Cutaneous and Plexiform Neurofibromas
Next, we tested 5mC and 5hmC levels to see if epigenetic changes in neurofibromas and MPNST were global. As with H3K27me3, immunoreactivity was generally preserved in nonneoplastic elements, even in tumors with pronounced loss (Fig. 1) . MPNST demonstrated a decrease in 5mC with median H-scores of 60 (range 10-160) and 8 (of 9) tumors demonstrating an H-score of 80. In contrast, the average 5mC H-scores for localized and plexiform neurofibromas were 120 (range 80-160) and 120 (range 80-180), respectively. The differences were statistically significant (p ¼ 0.0001, one-way ANOVA) (Fig. 2) . Importantly, we observed a positive correlation between 5mC and H3K27me3 levels (Pearson r ¼ 0.52, p ¼ 0.007).
When looking at 5hmC, the MPNST median H-score was 100 (range 80-160). The localized neurofibroma median H-score was 140 (range 80-160), and the plexiform neurofibroma median H-score was 120 (range 80-180). The decrease in 5hmC levels in MPNST versus neurofibromas was less pronounced than that of H3K27me3 and 5mC. The decrease reached borderline statistical significance (p ¼ 0.05, one-way ANOVA). All H-scores are provided per case in Table 2 . 
DISCUSSION
Human cancers are characterized by a plethora of genetic and epigenetic alterations (24) (25) (26) (27) . MPNST are known to feature genomic alterations affecting the function of the polycomb complex member PRC2. These alterations have been suggested to have profound consequences on the epigenetic constellation of tumor cells. Here, we report the first comprehensive global assessment of H3K27me3, 5mC, and 5hmC in benign nerve sheath tumors and MPNST, as well as demonstrate significantly reduced global levels of H3K27me3 and 5mC in MPNST compared to localized cutaneous neurofibromas, which are always benign, and plexiform neurofibromas, which are benign but have a potential for MPNST transformation. It is noteworthy that levels of H3K27me3, 5mc, and 5hmC were similar in localized cutaneous and plexiform neurofibromas despite clinical differences and putative cells of origin. Localized cutaneous neurofibromas have no potential for malignant transformation into MPNST and appear to be derived from stem/progenitor cells residing in the dermis, according to recent studies in model systems (28) . Conversely, plexiform neurofibromas have a potential to transform into MPNST and are derived from embryonic neural crest-derived progenitors (29, 30) .
A complex network of epigenetic regulators acts in concert to regulate epigenetic marks at different levels. More recent evidence suggests that alterations in histone modifications and DNA methylation changes are mechanistically linked through the polycomb group complex (10). Importantly, EZH2 and DNMTs share numerous target sites in the genome, suggesting a direct link between H3K27me3 and 5mC on a site-specific level. However, limited data is available on global levels of 5mC and H3K27me3 in tumors harboring alterations in the polycomb group complex.
Decreased levels of H3K27me3 in MPNST within our study agrees with previous data demonstrating loss of the methylated histone within MPNST (2, 9). Increased H3K27me3 levels have been correlated with gene silencing (8, 27, 31) , and loss of H3K27me3 as seen in MPNST has recently been associated with poor prognosis among MPNST (9) . Our data shows significant decrease of H3K27me3 in MPNST when compared to its benign counterparts, neurofibroma and plexiform neurofibroma, adding evidence to a decrease in H3K27me3 as an indicator of more aggressive behavior in peripheral nerve sheath tumors.
In addition to H3K27me3 loss in MPNST, 5mC was significantly decreased in MPNST compared to localized neurofibromas and plexiform neurofibromas. In general, increased levels of 5mC at promoters have been associated with transcriptional silencing, and decreased levels have been associated with a variety of tumor types (18, 20, (32) (33) (34) . The loss of polycomb and 5mC marks observed here suggests a global alteration in epigenetic plasticity and may explain in part the propensity of MPNST to show heterologous tissue differentiation. It is important to note that a strong positive correlation was observed between 5mC and H3K27me3 levels, supporting a potential mechanistic link between alterations in the PRC2 complex and DNA methylation changes. However, a subset analysis of MPNST revealed 1 case with discordant (high 5mC, low H3K27me3) H-scores. This observation stresses the fact that it is likely not a single mechanism contributing to the loss of 5mC and H3K27me3 in MPNST and emphasizes that epigenetic control mechanisms can be disrupted at different levels in solid tumors (33) . 5mC can be oxidized to 5hmC by TET enzymes (18, 20) and though the exact function of 5hmC remains unknown, decreased levels of 5hmC in tumor compared to normal tissue Decreased Global Methylation in MPNST have been reported (22, (34) (35) (36) . In our study, the extent of 5hmC decrease in MPNST was not as pronounced as 5mC. We previously studied 5mC and 5hmC levels in DIPG, another tumor type characterized by loss of H3K27me3 and global hypomethylation, though usually through mutation in H3K27 itself (H3-K27M). However, in DIPGs we found a paradoxical increase in 5hmC levels when compared with other high-grade gliomas (20) , which we hypothesized could be related to altered TET enzyme function and/or levels. It is possible that in MPNST global decreases in 5mC also affect 5hmC levels but to a lesser extent and that mechanisms involving TET or other enzymes are not operative in this tumor type. When looking at gliomas other than DIPG, decreased 5hmC in WHO Grade IV glioblastomas compared to WHO Grade I-III astrocytomas were observed (34, 35) as well as an association with worse survival among gliomas (34) , an observation that may extend to peripheral nerve sheath tumors.
In conclusion, we demonstrate for the first time reduced global levels of 5mC and 5hmC as well as confirm previously reported decrease in H3K27me3 levels in MPNST compared to neurofibromas and plexiform neurofibromas. The reduction in 5mC and 5hmC may be useful as an indicator of more aggressive tumor behavior in nerve sheath tumors and may also serve as a marker of methylation status useful for treatment selection in the future. Future studies defining the decreases of 5mC and 5hmC at specific DNA loci by whole genome sequencing may provide further insight into how PRC2 dysfunction and decreases in 5mC and 5hmC levels contribute to MPNST tumorigenicity. 
